EMA recommends temporary restriction on use of Lemtrada
The European Medicines Agency (EMA) has started a review of Lemtrada (alemtuzumab) following reports of side effects affecting the heart, blood vessels, liver and immune system. These side effects are rare but potentially serious.
As a temporary measure while the review is being carried out, the EMA has advised that Lemtrada should only be started in people with relapsing remitting MS that continues to be very active despite taking at least two disease modifying drugs (DMDs) or where other DMDs cannot be taken.
If you have already started Lemtrada and are due to receive further infusions, you should continue with treatment. Anyone who has been treated with Lemtrada should continue to have monthly blood and urine tests for four years after the last treatment course.
If you have concerns, you should talk to your neurologist or MS nurse.
Find out more
- European Medicines Agency news item
- Lemtrada
- MS Decisions - a guide to disease modifying drugs


My search for MS support while studying for a PhD
4 Mar 2021 - 00:00
Laura is studying a PhD in Cancer Genomics and was diagnosed with MS in September 2020 following multiple hospital admissions. Here, Laura talks about how this affected her mental health and what more could be done to support other students going through the same thing.


MS, my mental health and a university degree
4 Mar 2021 - 00:00
Scarlet talks about how she learnt to manage her MS and mental health alongside the stresses of completing a university degree.


Receiving an MS diagnosis during my gender transition
22 Feb 2021 - 00:00
Chris shares his experience of being diagnosed with MS at the same time as starting hormone treatment and a surgical gender transition.

Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.